Ntokou I S, Boletis J N, Apostolaki M, Vrani V, Zavos G, Kostakis A, Iniotaki A
National Tissue Typing Centre, General State Hospital "G. Gennimatas", Athens.
Clin Transpl. 2011:341-50.
Between 2000 and 2010, 4241 sera from 597 renal transplant (RTx) recipients were monitored for DSA development. The patients were selected in the absence of immunological memory to donor HLA before RTx and were divided into two groups: the historic group, consisting of patients transplanted before December 1996 and the study group, consisting of those transplanted after December 1996. Ninety-two out of 597 (15.4%) patients developed de novo DSA post-RTx, while 196 had third party anti-HLA antibodies. DSA were more frequent in the historic group compared with the study group (P < 0.001). Anti-HLA class-III DSA predominated in both groups (84.6% vs. 69.7%) and were directed preferentially against donor HLA-DQ (65/92,70.6%). Recipients of class II-incompatible grafts developed DSA more frequently than those receiving class II-compatible grafts (P = 0.003). DSA production was not different between pre-sensitized and non-sensitized patients (P = 0.842). DSA class I (HR = 31.78), DSA class II (HR = 20.92), and non-DSA (HR = 5.94) were the only independent predictors for graft failure. In conclusion, this study shows the results of long-term post-transplant alloantibody monitoring, and confirm the strong association of DSA and graft loss. Protocols that remove anti-HLA antibodies from RTx recipients may benefit allograft survival.
在2000年至2010年期间,对597例肾移植(RTx)受者的4241份血清进行了监测,以观察供者特异性抗体(DSA)的产生情况。这些患者在肾移植前对供者人类白细胞抗原(HLA)不存在免疫记忆,并被分为两组:历史组,由1996年12月之前接受移植的患者组成;研究组,由1996年12月之后接受移植的患者组成。597例患者中有92例(15.4%)在肾移植后出现了新发DSA,而196例患者有第三方抗HLA抗体。与研究组相比,历史组中DSA更为常见(P<0.001)。两组中抗HLA-III类DSA均占主导(84.6%对69.7%),且优先针对供者HLA-DQ(65/92,70.6%)。接受II类不相容移植物的受者比接受II类相容移植物的受者更频繁地产生DSA(P = 0.003)。预致敏患者和非致敏患者之间的DSA产生情况没有差异(P = 0.842)。I类DSA(风险比[HR]=31.78)、II类DSA(HR = 20.92)和非DSA(HR = 5.94)是移植物失败移植失败的唯一独立预测因素。总之,本研究显示了移植后长期同种异体抗体监测的结果,并证实了DSA与移植物丢失之间的密切关联。从肾移植受者中清除抗HLA抗体的方案可能有益于同种异体移植物存活。